Diagnostic Projects

Parallel to the therapeutic approaches the Neuroallianz Consortium plans three diagnostic development projects. These diagnostics shall enable an individual early diagnosis of neurodegenerative diseases.

List of diagnostic Neuroallianz projects: 

  • D5: Human cell-based test-system for cytopathological processes of Alzheimer‘s dementia
  • D7: Blood assay for early and predictive diagnostics for Alzheimer‘s dementia
  • D9: Serum microRNAs as non-invasive biomarker in Epilepsy
  • D10: In-silico discovery of biomarkers in neurological disease
  • D11 B: PET ligands as in-vivo diagnostics for neuroinflammatory, neurodegenerative, and neurooncological diseases
  • D13 B: Identification of prediction and progression biomarkers in the earliest stages of PD
  • D17 B: Multi-modality biomarker for long-term prediction and staging of probable Alzheimer’s disease in pre-demented subjects
  • D18 B: Triggered Abeta Efflux (TEP-TRIG)
  • D19 B: Depletion of disturbing antibodies for biomarker-based monitoring of immunotherapeutic clinical studies of Alzheimer’s disease
© Fotolia – Peter Atkins

Facts

To provide the German location of biotechnology and pharma industry with fresh impulsion, the German Federal Ministry for Education and Research (BMBF) started the pharma initiative "BioPharma: The Strategy Competition for Future Medicines". The Neuroallianz Consortium was nominated for this initiative.

The Neuroallianz Consortium has created a novel strategic partnership where various academic institutions and companies are working jointly on innovative diagnostic and therapeutic research projects. The aim is to efficiently transform research into benefits for the patients.

Main focuses are diagnostic and therapy of neurodegenerative diseases such as Parkinson's Disease, or Alzheimer's Dementia, and Epilepsy.

Duration: 2009 – 2018

Budget: 40 Mio. €

Logo BMBF